Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-Label Extension Study of UT-15C SR (oral treprostinil) in Pulmonary Arterial Hypertension
2006-000804-18Phase 3Completed
- Sponsor
- United Therapeutics Corporation
- Start
- Nov 2006
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of treprostinil in Plexogenic Pulmonary Arteriopathy, pulmonary arterial hypertension (PAH) and pulmonary hypertension (PH), sponsored by United Therapeutics Corporation. Primary endpoint: Change in 6-minute walk distance at 12 months. Started Nov 2006; status: completed.
02
Drugs
treprostinil
03
Conditions
Plexogenic Pulmonary Arteriopathypulmonary arterial hypertension (PAH)pulmonary hypertension (PH)
Beyond the preview
Go deeper on 2006-000804-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-000804-18.